In our own studies, mice with combined early deletion of Tet2 and Tet3 in developing B cells using Mb1-Cre developed progressive B cell lymphoma and succumbed to disease within 5–6 months of age, an earlier onset compared to 15–20 months observed in Tet1/2-deficient mice (46, 113). This evidence concerns the gene TET2 and B-cell non-Hodgkin lymphoma.